Drug-metabolizing enzymes (DMEs) biotransform several toxins and xenobiotics in both tumor and normal cells, resulting in either their detoxification or their activation. Since DMEs also metabolize several chemotherapeutic drugs, they can significantly influence tumor response to chemotherapy and susceptibility of normal tissues to collateral toxicity of anticancer treatments. This review discusses the pharmacogenetics of DMEs involved in the metabolism of drugs which constitute the backbone of osteosarcoma (OS) chemotherapy, highlighting what is presently known for this tumor and their possible impact on the modulation of future treatment approaches. Achieving further insight into pharmacogenetic markers and biological determinants related to treatment response in OS may ultimately lead to individualized treatment regimens, based on a combination of genotype and tumor characteristics of each patient.
Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*A
Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase
The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies
Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target
Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily
Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin
The polymorphic human glutathione transferase T1-1, the most efficient glutathione transferase in the denitrosation and inactivation of the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.
Mechanism of the glutathione transferase-catalyzed conversion of antitumor 2-crotonyloxymethyl-2-cycloalkenones to GSH adducts
High-throughput detection of glutathione s-transferase polymorphic alleles in a pediatric cancer population
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)
Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene
An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment
Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents
Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients
Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment
CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma
Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations.
Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy
Ectopic Expression of Ankrd2 Affects Proliferation, Motility and Clonogenic Potential of Human Osteosarcoma Cells.
Cancer Metabolism: Therapeutic Targets
Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.
In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.